Overview

Beta-Adrenergic Modulation of Drug Cue Reactivity

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oklahoma
Collaborators:
Duke University
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
Oklahoma State University Center for Health Sciences
Treatments:
Nicotine
Propranolol